State Street’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

State Street’s Portfolio NVIV Stock Details NVIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8,795	Closed	-$76K	–	5053
2022 Q1	$76K	Buy	8,795 +86	+1%	+$819	﹤0.01%	4714
2021 Q4	$100K	Hold	8,709	–	–	﹤0.01%	4582
2021 Q3	$152K	Hold	8,709	–	–	﹤0.01%	4448
2021 Q2	$162K	Buy	+8,709	New	+$166K	﹤0.01%	4265
2018 Q2	–	Sell	-1	Closed	-$12K	–	3864
2018 Q1	$12K	Hold	1	–	–	﹤0.01%	3735
2017 Q4	$17K	Hold	1	–	–	﹤0.01%	3698
2017 Q3	$34K	Sell	1 -20	-95%	-$615K	﹤0.01%	3690
2017 Q2	$1.04M	Sell	21 -4	-16%	-$218K	﹤0.01%	3332
2017 Q1	$1.88M	Buy	25 +2	+9%	+$162K	﹤0.01%	3102
2016 Q4	$1.83M	Buy	23 +1	+5%	+$89.4K	﹤0.01%	3127
2016 Q3	$2.85M	Hold	22	–	–	﹤0.01%	2835
2016 Q2	$2.37M	Buy	22 +1	+5%	+$118K	﹤0.01%	2962
2016 Q1	$2.79M	Buy	21 +3	+17%	+$322K	﹤0.01%	2860
2015 Q4	$2.46M	Hold	18	–	–	﹤0.01%	2912
2015 Q3	$2.84M	Buy	18 +4	+29%	+$935K	﹤0.01%	2833
2015 Q2	$4.38M	Buy	+14	New	+$3.7M	﹤0.01%	2692

Other funds holding NVIV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

State Street's NVIV Position: Q2 2022 in Review

State Street sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2022, closing a stake of 8,795 shares — an estimated $76K sold.

State Street first reported a position in NVIV in Q2 2015 and held it in 16 quarters. The position peaked at $4.38M in Q2 2015. 13 funds tracked by Wall St. Rank hold NVIV as of Q2 2022.

State Street reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2022 after selling out during the quarter.
State Street sold 8,795 InVivo Therapeutics Holdings Corp shares in Q2 2022, an estimated $76K.
State Street first reported a position in InVivo Therapeutics Holdings Corp in Q2 2015 and held it in 16 quarters.
State Street's InVivo Therapeutics Holdings Corp position peaked at $4.38M in Q2 2015.
13 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2022.

Based on State Street's 13F filing for Q2 2022, filed 15 Aug 2022.